Integral Molecular, a company discovering antibodies against multipass membrane proteins, has launched fully optimised, high-affinity lead monoclonal antibodies against Claudin 18.2 (CLDN18.2), a structurally complex oncology target overexpressed on various solid tumours, it was reported on Tuesday.
The CLDN18.2 antibodies found using the firm's MPS antibody discovery platform are ready to progress towards preclinical studies and are completely humanised, unlike the Phase 3 clinical benchmark.
Integral Molecular showcased its CLDN18.2 MAbs at the virtual PEGS Europe (Protein & Antibody Engineering Summit) earlier this month. CLDN18.2 is expressed in multiple cancers, including lung, pancreatic and oesophageal cancers, but indicates limited expression in healthy adult tissue.
Ross Chambers, VP of Antibody Discovery, said, 'The structural complexity of CLDN18.2 and the widespread expression of closely related family members has made discovery of highly specific antibodies against CLDN18.2 challenging. Our exquisitely specific, picomolar affinity lead candidates show stronger binding than the most advanced clinical antibody and are a testament to the ability of our platform to yield antibodies against difficult targets.'
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review